TQ05105
As of the edition of 20 October 2026, TQ05105 is a drug known only by a code name: in active development; acts on JAK2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Code name only
- Registered trials
- 14, 3 stopped early
- Disease areas
- Blood and lymph; Immune system; Lungs and airways; Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| JAK2 | Tyrosine-protein kinase JAK2 | O60674 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 8 | 4 | 2 | 1 |
| Phase 2 | 6 | 1 | 3 | 2 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Chia Tai Tianqing Pharmaceutical | Lead sponsor of trials | 2018 to now |